6.
Choi Y, Kim Y
. Beneficial and Detrimental Roles of Heme Oxygenase-1 in the Neurovascular System. Int J Mol Sci. 2022; 23(13).
PMC: 9266949.
DOI: 10.3390/ijms23137041.
View
7.
Pramanik D, Dey S
. Active site environment of heme-bound amyloid β peptide associated with Alzheimer's disease. J Am Chem Soc. 2010; 133(1):81-7.
DOI: 10.1021/ja1084578.
View
8.
Hare D, Ayton S, Bush A, Lei P
. A delicate balance: Iron metabolism and diseases of the brain. Front Aging Neurosci. 2013; 5:34.
PMC: 3715022.
DOI: 10.3389/fnagi.2013.00034.
View
9.
Zhao R, Jiang S, Zhang L, Yu Z
. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int J Mol Med. 2019; 44(1):3-15.
PMC: 6559295.
DOI: 10.3892/ijmm.2019.4188.
View
10.
Hannemann F, Bichet A, Ewen K, Bernhardt R
. Cytochrome P450 systems--biological variations of electron transport chains. Biochim Biophys Acta. 2006; 1770(3):330-44.
DOI: 10.1016/j.bbagen.2006.07.017.
View
11.
Ogawa K, Sun J, Taketani S, Nakajima O, Nishitani C, Sassa S
. Heme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1. EMBO J. 2001; 20(11):2835-43.
PMC: 125477.
DOI: 10.1093/emboj/20.11.2835.
View
12.
Wu Y, Hsieh H
. Roles of Heme Oxygenase-1 in Neuroinflammation and Brain Disorders. Antioxidants (Basel). 2022; 11(5).
PMC: 9137505.
DOI: 10.3390/antiox11050923.
View
13.
Zamocky M, Gasselhuber B, Furtmuller P, Obinger C
. Turning points in the evolution of peroxidase-catalase superfamily: molecular phylogeny of hybrid heme peroxidases. Cell Mol Life Sci. 2014; 71(23):4681-96.
PMC: 4232752.
DOI: 10.1007/s00018-014-1643-y.
View
14.
Olsson M, Allhorn M, Bulow L, Hansson S, Ley D, Olsson M
. Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for α(1)-microglobulin. Antioxid Redox Signal. 2012; 17(5):813-46.
DOI: 10.1089/ars.2011.4282.
View
15.
Srinivasan E, Chandrasekhar G, Chandrasekar P, Anbarasu K, Vickram A, Karunakaran R
. Alpha-Synuclein Aggregation in Parkinson's Disease. Front Med (Lausanne). 2021; 8:736978.
PMC: 8558257.
DOI: 10.3389/fmed.2021.736978.
View
16.
Cuadrado A, Rojo A, Wells G, Hayes J, Cousin S, Rumsey W
. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019; 18(4):295-317.
DOI: 10.1038/s41573-018-0008-x.
View
17.
Ashraf A, Dani M, So P
. Low Cerebrospinal Fluid Levels of Hemopexin Are Associated With Increased Alzheimer's Pathology, Hippocampal Hypometabolism, and Cognitive Decline. Front Mol Biosci. 2021; 7:590979.
PMC: 7775585.
DOI: 10.3389/fmolb.2020.590979.
View
18.
Goebel U, Wollborn J
. Carbon monoxide in intensive care medicine-time to start the therapeutic application?!. Intensive Care Med Exp. 2020; 8(1):2.
PMC: 6952485.
DOI: 10.1186/s40635-020-0292-8.
View
19.
Takahashi M, Dore S, Ferris C, Tomita T, Sawa A, Wolosker H
. Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron. 2001; 28(2):461-73.
DOI: 10.1016/s0896-6273(00)00125-2.
View
20.
Levi S, Luzzago A, Cesareni G, Cozzi A, Franceschinelli F, Albertini A
. Mechanism of ferritin iron uptake: activity of the H-chain and deletion mapping of the ferro-oxidase site. A study of iron uptake and ferro-oxidase activity of human liver, recombinant H-chain ferritins, and of two H-chain deletion mutants. J Biol Chem. 1988; 263(34):18086-92.
View